Model human disease and identify predictive biomarkers of response

Fill in the form to watch our presentation

organoids are us

Talk highlights

Drug discovery and development should be performed using advanced preclinical models, directly derived from patient tissue, that can predict clinical response. This will improve patient stratification and the identification of predictive biomarkers, before a single patient has been dosed. In this presentation Dr. Rob Vries, CEO at HUB will discuss:

  • How HUB Organoids™ bridge the gap between the lab and clinic, offering more clinically relevant in vitro models that faithfully mimic human disease pathology and physiology
  • That HUB Organoids can effectively predict patient response when used in drug screen, thus improving the current drug discovery and development process